Literature DB >> 20437117

STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction.

Shawnta Coleman1, Aminah Jatoi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437117     DOI: 10.1007/s11912-010-0102-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


× No keyword cloud information.
  4 in total

1.  Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

Authors:  Lynne I Wagner; Mario E Lacouture
Journal:  Oncology (Williston Park)       Date:  2007-10       Impact factor: 2.990

2.  Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

Authors:  Aminah Jatoi; Kendrith Rowland; Jeff A Sloan; Howard M Gross; Paul A Fishkin; Stephen P Kahanic; Paul J Novotny; Paul L Schaefer; David B Johnson; Loren K Tschetter; Charles L Loprinzi
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

Review 3.  Rash from EGFR inhibitors: opportunities and challenges for palliation.

Authors:  Benjamin M Solomon; Aminah Jatoi
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

4.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.

Authors:  Alon Scope; Anna Liza C Agero; Stephen W Dusza; Patricia L Myskowski; Jocelyn A Lieb; Leonard Saltz; Nancy E Kemeny; Allan C Halpern
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

  4 in total
  1 in total

1.  Xerosis and pruritus as major EGFRI-associated adverse events.

Authors:  Julia M K Clabbers; Christine B Boers-Doets; Hans Gelderblom; Theo Stijnen; Mario E Lacouture; Koos J M van der Hoeven; Adrian A Kaptein
Journal:  Support Care Cancer       Date:  2015-06-27       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.